In Russia, lutetium-177 is used to treat neuroendocrine tumors for the first time

The Federal State Budgetary Institution Scientific Research Center for Radiology of the Ministry of Health of Russia has successfully utilized a Russian radiopharmaceutical drug based on lutetium-177 to treat patients with metastatic and inoperable neuroendocrine tumors for the first time. Both patients were diagnosed with a neuroendocrine tumor of the pancreas, progressing against the background of standard chemotherapy.

The drug was synthesized in the nuclear pharmacy of the National Medical Research Center of Radiology. As it turned out during post-therapy scanning, the distribution of the drug achieved high accuracy. The therapeutic effect will be assessed later, after a few weeks. “Treatment that was not available in Russia has now become available both to our fellow citizens and to patients from other countries,” the press service emphasized.

Source